Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.


  • Holman, Rury R
  • Bethel, Mary A
  • Chan, Juliana CN
  • Chiasson, Jean-Louis
  • Doran, Zoë
  • Ge, Junbo
  • Gerstein, Hertzel Chaim
  • Huo, Yong
  • McMurray, John J
  • Ryden, Lars
  • Liyanage, Winitha
  • Schröder, Stefan
  • Tendera, Michal
  • Theodorakis, Michael J
  • Tuomilehto, Jaakko
  • Yang, Wenying
  • Hu, Dayi
  • Pan, Changyu

publication date

  • July 2014